Symbol="IMMX"
AssetType="Common Stock"
Name="Immix Biopharma Inc"
Description="Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology and inflammation in the United States and Australia. The company is headquartered in Los Angeles, California."
CIK="1873835"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="34876800"
EBITDA="-9407644"
PERatio="None"
PEGRatio="None"
BookValue="0.844"
DividendPerShare="0"
DividendYield="0"
EPS="-0.62"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.354"
ReturnOnEquityTTM="-0.599"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.62"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="11"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="1.156"
EVToRevenue="-"
EVToEBITDA="-0.0128"
Beta="None"
num_52WeekHigh="3.29"
num_52WeekLow="0.68"
num_50DayMovingAverage="2.244"
num_200DayMovingAverage="1.881"
SharesOutstanding="15033100"
DividendDate="None"
ExDividendDate="None"
symbol="IMMX"
open="2.35"
high="2.37"
low="2.26"
price="2.32"
volume="86192.00"
latest_trading_day="2023-07-11"
previous_close="2.29"
change="0.03"
change_percent="1.3100%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="65"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="35"
Volume_recent_avg="244895"
Change_recent_avg="0.01"
Delta_recent_avg="0.21"
Variance_recent_avg="0.1"
Change_ratio_recent_avg="-0.26"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="35"
Aroon_momentum_negative="65"
image_negative_thumbnail_id_1="511"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0094.jpeg"
image_negative_thumbnail_id_2="1096"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0129.jpeg"
image_neutral_thumbnail_id_1="585"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0014.jpeg"
image_neutral_thumbnail_id_2="521"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0078.jpeg"
image_positive_thumbnail_id_1="701"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0007.jpeg"
image_positive_thumbnail_id_2="949"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0111.jpeg"
image_professor_thumbnail_id_1="1169"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0003.jpeg"
image_professor_thumbnail_id_2="1203"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0037.jpeg"
